Drug intelligence / Profile preview

aspirin + sertraline

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Aspirin + sertraline is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins and thromboxanes, which results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons, primarily used for the treatment of depression and anxiety disorders. The combination may be encountered in clinical practice when both pain/inflammation management and antidepressant therapy are required; however, co-administration increases the risk of bleeding due to additive effects on platelet function[1][7]. This combination should be used with caution under medical supervision.

02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SIGMAR1 (Sigma non-opioid intracellular receptor 1)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on aspirin + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + sertraline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call